BioAtla, Inc. (BCAB) Dividend History

BioAtla, Inc. (BCAB) is a biotechnology company focused on developing next-generation antibody-based therapeutics for cancer and other serious diseases. The company specializes in its proprietary AZCT (A priori, Target, and Location-Validated Antibody-Drug Conjugate) platform, which aims to create targeted treatments with improved safety and efficacy. BioAtla's pipeline includes innovative immuno-oncology and targeted therapy candidates.

11085 Torreyana Road, San Diego, CA, 92121
Phone: 858-558-0708
Website: https://www.bioatla.com

Dividend History

BioAtla, Inc. currently does not pay dividends

Company News

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

BioAtla presented first-in-human data on BA3182, a dual-conditionally binding EpCAM x CD3 bispecific T-cell engager, showing preliminary tumor reductions and a low-grade safety profile in patients with treatment-refractory metastatic adenocarcinoma.

GlobeNewswire Inc.
Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Cyanotech The Trade: Cyanotech Corporation (NASDAQ: CYAN) Director Michael Davis acquired a total of 400,000 shares an average price of $1.00. To acquire these shares, it cost around $400,000. What’s Happening: On Nov. 8, Cyanotech posted a narrower loss for the second quarter. What Cyanotech Does: Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market. BioAtla The Trade: ...

Benzinga

Featured Companies: CRDF XAIR
Does BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect?

The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research
Tracking Baker Brothers Portfolio - Q2 2021 Update

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The top three positions add up to almost ~62% of the portfolio.

Seeking Alpha

Featured Companies: ABCL ACAD ADCT ALGS ALKS APLS AXSM BCRX BMRN CERS DBVT DSGN FLGT HRTX IGMS IMTX INCY INSM KNSA KOD KRYS KYMR MDGL MRUS NBIX NRIX NVAX PACB PRLD RARE RYTM TCRX TIL VERV VSTM

Page data last updated 07/26/2025 01:32:24 UTC